Novo Slashes GLP‑1 Prices; Palvella Spikes on Data
Novo to cut GLP-1 drug prices; Palvella soars on study data https://t.co/UAs4IETgPX $NVO $PVLA+ 32% $GOSS $VNDA $PFE #biotech
Stop Revenue Leaks: Tighten RCM Processes Now
Every org struggles with RCM—but not every org fixes what’s leaking revenue. This look at denials, claim errors, and today’s patient-pay realities makes the case for tightening processes now. https://t.co/lWo3nK666k #RCMFix #HITsm #HITSM #TempDev
Health Insurance: So Complex Even a Quiz Stumps You
We have a new quiz on how health insurance works. But, it's really a statement about how utterly complex health insurance is in the U.S. https://www.kff.org/private-insurance/quiz-how-well-do-you-understand-your-health-insurance/
Roctavian Withdrawn, Exposing Science‑to‑market Gap
Failing to find a buyer, BioMarin is voluntarily withdrawing Roctavian from the market. A fitting end for what was once one of the highest-profile gene therapies in development — and a reminder of the gap between promising science and a viable...
Leaders Optimistic on AI-Driven Clinical Innovation, Wary of Costs
This survey of leaders from #healthcare plans, health systems, and innovative solution providers reflects optimism about clinical innovation and emerging #AI use, balanced against concerns over costs, payment models, and politics: https://t.co/xFXpbqfhbY via @TTCapPartners https://t.co/tG3a2CGn90
AI Will Replace Most Knowledge Workers; Healthcare Stays Last
SaaS may be in its bloodbath moment but as @Bob_Wachter says: When AI replaces doctors it means we are all out of jobs. Doctors, writers, lawyers, consultants, knowledge workers, etc. Healthcare is highest regulation, liability, risk. It’ll be one of the...
Unseen Miracles Shaping Our Everyday Reality
The Miracles You’re Living Through (And Don’t Even Notice) by @PeterDiamandis and @Steven_Kotler https://t.co/jB8O0q00KT https://t.co/21Snf2EBxG
Novo Highlights New Data on Triple‑Target Obesity Therapy
Novo, searching for a spark, spotlights new data for three-pronged obesity drug https://t.co/pPo9Oc1wlF $NVO $LLY #obesity
FDA Draft Guidance Boosts Individualized Therapy Innovation
FDA Issues Plausible Mechanism Pathway Draft Guidance to Spur Innovation for Individualized Therapies https://t.co/OZW6Q27zMa via @Inside_PM
Big Tech Accelerates Into Healthcare With Partnerships
Big tech companies like Amazon, Google/Alphabet, Apple, NVIDIA and Microsoft are taking their move into healthcare and medicine seriously. They are developing new, health-related features on their platforms. They are also teaming up with research institutions and developers to create new...
AI-Driven Care Models Enhance Long-Term Cancer Survivors' Quality
As more patients live years—sometimes decades—beyond a cancer diagnosis, we need smarter, sustainable care models focused on improving quality of life. At @Oracle, we're use AI and real-world evidence to advance smarter, more equitable cancer care: https://t.co/h28j1sIrN3
Budapest’s Turbine Secures $25M to Simulate Lab Experiments
The latest AI biotech raise comes not from the Bay Area or Boston, but out of Budapest Turbine has closed a $25M Series B, planning to build AI models that can simulate more and more lab experiments: https://t.co/Q31DVENA9G
Switching to Syai CGM for Easier Glucose Monitoring
I just started testing a new continuous glucose monitor (CGM) device from Syai. I tried Abbott Freestyle Libre 2 and Sibionics before, but the need for the reader with Libre was a pain in the process, and the Sibionics app is...
Slate Secures $130M, Launches Chinese Headache Drug
Slate starts up with $130M and a headache drug from China https://t.co/6DEltQAI8s by @gwendolynawu #biotech #startups $HLUBF
Swallowable Robots Promise Safer, Remote Diagnostics
The future of medicine might be something you swallow. When I first read about PillBot, I paused. A tiny ingestible robot camera that replaces traditional endoscopies? That is not incremental innovation. That is a shift. Instead of invasive tubes and hospital procedures,...
China’s Health AI App Hits 100 Million Users Worldwide
The world’s largest health-focused AI app is from China now, with over 100 million (!) users. Ant Group just released this number and more details of what their plans are with the app. "Among its new users, 52% came from third-tier cities...
Vevye Rapidly Narrows Gap to Miebo Despite Head Start
So the key here is look at how quickly $HROW's Vevye is catching up with $BLCO's Miebo - this is happening despite the Miebo head start (which provides a waterfall effect from refills) and way more extensive detailing and DTC...
Prime-Edited Therapy Restores Immune Function in Teen
Below is the story of the first patient treated with a prime-edited therapeutic, developed by @PrimeMedicine in a trial led by Dr. Élie Haddad and his team at CHU Sainte-Justine. This teenager suffered from chronic granulomatous disease (CGD), an immunodeficiency,...
Take Back Our Food System: Choose Whole, Demand Better
Even our junk food is getting worse. Our food system has been hijacked, but we can take it back. Read labels. Choose whole foods. Demand better. h/t @drmarkhyman
AI Personal Trainer Revolutionizes Strength Training
I love my new AI personal trainer. In addition to knowing all my metabolic parameters & strength of each of my muscle groups, she also identifies imbalances and helps me correct it. Is this the future of strength training? https://egym.com/us
Engage Caregivers Early to Make AI a Support Tool
AI adoption in healthcare coding starts with people. Nick Judd of Cleveland Clinic shares why engaging caregivers from day one helped teams see generative AI as a support tool—not a replacement. 🔗https://t.co/cMNcrP9ZWl @ClevelandClinic @DukeHealth #AKASA #AHIMA25 #HITSM https://t.co/FtfPW5BWKP
CMS Plans AI‑Driven Overhaul of Medicare Enrollment Process
NEW: The entire process of finding Medicare coverage may be influenced by artificial intelligence in the not-too-distant future. CMS wants to use AI tools for its "Medicare Experience Modernization" project — and there are lots of question marks. https://t.co/uSLFlAxViJ https://t.co/2bP3HnEDBx
FDA Issues Guidance on New Individualized Therapy Pathway
Building off the Baby KJ success story: FDA unveils long-awaited guidance on new pathway for individualized therapies - https://t.co/Uetp1cGFq2
IPO Priced at $15‑$17, Valuing Firm at $2 B
Generate estimated it would price its shares at $15 to $17 apiece, translating to a valuation ranging from $1.91 billion to $2.17 billion — not counting an underwriter's option: https://t.co/n9nJsbJuvm
Inclusive Design with Disabled Communities Drives Innovation
Fostering relationships with disabled communities could invite meaningful feedback during the design of assistive technologies, which could spark innovations that serve diverse populations. Learn more in Science #Robotics: https://t.co/NmJ6c2KIS5 https://t.co/zlhagQkRbw
BCAX's Phase 3 Ficera Dose Raises Critical Concerns
Why is $BCAX testing a ficera dose in phase 3 that it now says isn't optimal (and other uncomfortable questions)? Via @ApexOnco -> https://t.co/mLWKP6AAZ9 $JNJ $GMAB
Prepare Now: Aging Care Will Soon Be Everyone's Reality
As someone researching aging during a time when everyone is trying to extend lifespan (and not necessarily healthspan), I beg you to read this entire🧵. Unless something changes, this is your future reality. You may already be dealing with this if...
Rival Drug Wins, Costs Us Marketing Gold
That feeling you get when you run a head-to-head study and the rival drug beats you out. Spending a fortune to hand your competitor a marketing message. Sometimes it feels like $NOVO is snake bit. $LLY https://t.co/gGUjl6iqPg
Bayesian Designs Decide Faster than Frequentist Group Sequential Methods
Goal-Driven Flexible Bayesian Design presentation updated w/comparison of performance of frequentist group sequential designs: https://t.co/QCZ6DQrm07 . Frequentist approach takes far too long to make a decision by controlling something that is NOT an error prob. #Statistics #rct https://t.co/X2knbmzTuX
Trump's Drug Pricing Deals Promise Lower Consumer Costs
My @CNBC segment on how President Trump's drug pricing deals will achieve many of the initial aims set out by tariff proposals, with respect to reshoring drug manufacturing, and how the biggest consumer impact in terms of lower drug costs...
Doctor-in-the-Loop AI Enh
Evaluating a doctor-in-the-loop AI-agent for multiple myeloma chart reviews [Nov 3, 2025] Karla Mariana Castro Bórquez et al. @HealthTree #ASH25 abs25-15262 PID 4424 https://t.co/MvBeHqOxCg #mmsm #AI #EMR #RWD https://t.co/onY817NfVr
Histopathology Genomics Predicts Myeloma Risk in 1,429 Patients
Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants [Nov 3, 2025] Rajanna et al. @DrOlaLandgren #ASH25 abs25-11635 PID 4008 https://t.co/gOprMCjfgh #mmsm #AI #oncopath https://t.co/pjikEsgfHC
Race‑agnostic AI Accurately Predicts M‑protein in Myeloma
Race agnostic models maintain accuracy in predicting M-protein levels in multiple myeloma [Nov 3, 2025] @rahul2u et al. #ASH25 abs25-11347 PID 2810 https://t.co/A27ozBoW8h #mmsm #AI #CancerDisparities https://t.co/ubJ6NGMFUE
Unstructured Serum Data Hinders AI in Myeloma Care
Unstructured serum electrophoresis data limits real world AI models in multiple myeloma: Evaluation of 384 institutions across United States [Nov 3, 2025] @MalekEhsanMD et al. #ASH25 abs25-11278 PID 2809 https://t.co/mAC8l7xnaG #mmsm #cancerdisparities #hpeonc https://t.co/veJxBV5S0N
Patients Favor Step‑Up Dosing for Teclistamab, Talquetamab
Patient perspectives & preferences for step-up dosing and treatment w/ teclistamab & talquetamab: Insights from a patient survey [Nov 3, 2025] @JayHydren et al. @RahulBanerjeeMD abs25-8335 PID 6354 https://t.co/pRlflaSb2I #mmsm #Tcellrx @HealthTree https://t.co/3I9nwsxZMx
Patient‑Centered Registry Accelerates Multiple Myeloma Care
The HealthTree Cure Hub registry: A patient-centered, multicenter approach to advancing multiple myeloma care - Jorge Arturo Hurtado Martínez et al. @HealthTree #ASCO25 Abst e19569 https://t.co/X2pdaIDYth #mmsm
Most Myeloma Patients Prefer Shared Decision‑Making
Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey [Dec 7, 2024] @ManniMD1 et al. - @HealthTree https://t.co/jATJRKEfB2 #ASH24 Abst 2281 #mmsm HT @Taxkourel
Side Effect Severity Shapes Patient Autonomy in Myeloma Care
Patient-Centered Care in Hematology: How Side Effect Severity Influences Decision-Making Autonomy in Relapsed Refractory Multiple Myeloma [Dec 8, 2024] Martinez et al. #ASH24 Abst 706 https://t.co/l7SHPBwbna #mmsm HT @Taxkourel
Strong Care Team Ties Shape Myeloma Treatment Choices
The effect of care team-patient relationship on decision-making in relapsed/refractory multiple myeloma - @MyelomaTeacher et al. @HealthTree #ASCO24 Abstract e19530 https://t.co/Ss5LZHH0Oj #mmsm
Patients Reveal Hopeful Views on Myeloma Cure
A survey on the patient perspective on cure in multiple myeloma [Oct 9, 2022] @ManniMD1 et al. @HealthtreeMM @TheLancetHaem https://t.co/1XhKT7AWGi #mmsm
Patient‑Driven Platform Accelerates Multiple Myeloma Research
.@HealthtreeMM Hub: A Patient-Derived, Patient-Driven Clinical Cancer Information Platform Used to Overcome Hurdles & Accelerate Research in Multiple Myeloma [3/10/22] @NSweeneyPhd @AhlstromJenny @FaithEDavies1 @mtmdphd @JCOCCI_ASCO https://t.co/WOwLb9Eozv @myelomacrowd #mmsm https://t.co/dZzhU3N32Q
Patient Portal Streamlines Myeloma Imaging and Pathology Reporting
. @HealthtreeMM Patient Portal mediated myeloma patient reported diagnostic imaging and pathology testing - @NSweeneyPhd @AhlstromJenny @mtmdphd J Clin Oncol 38: 2020 (suppl; abstr e20565) #ASCO20 https://t.co/CRLXETpeMm #mmsm #oncorad #oncopath https://t.co/m1UGDimLWm
Low‑dose Dexamethasone Improves Survival in Newly Diagnosed Myeloma
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol https://t.co/hXxlFINejC #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm https://t.co/FjBnt6yIox
Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/QdWETmSoiR
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor‑Dex for Myeloma‑Induced Kidney Damage
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/paGRlHV1Dv
Bandages Evolve: From Passive Cover to Active Healing
Bandages have been a central component of wound healing for centuries. In the digital health era, the wound healing process will transform the role of bandages from a passive to an active one. We dive into the current and future innovations of...
Critical Thinking Must Outpace AI in Healthcare
Jan Herzhoff, president of global health businesses at Elsevier, emphasized the importance of critical thinking over sole reliance on AI to prevent de-skilling in healthcare at the India AI Impact Summit 2026. https://t.co/hexOguFdCt #AI #Elsevier #health #India
AI's Role in Medicine Explored on NPR's Pulse
Really enjoyed this conversation with @MaikenScott on her @NPR show, @WHYYThePulse, about my book, "A Giant Leap" and how AI will shape the future of medicine. https://t.co/Nw17vwApkg
Women Need Transparent Testosterone Data in Menopause Care
Had a great conversation with Dr. Rebecca Dunsmoor-Su from ovary_active and @mygennev about telemedicine and menopause and many other things. Hope you head to TheVajenda.com for the full interview. Here is a clip of us discussing why women deserve data...
AI Health Alerts Force Companies to Choose Duty over Silence
In 2026, software doesn’t just store health data - AI allows it to see medical risk before anyone else. When consumers use AI for their health, we are increasingly faced with the dilemma of whether AI companies have a duty...